JPWO2020030927A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020030927A5
JPWO2020030927A5 JP2021506986A JP2021506986A JPWO2020030927A5 JP WO2020030927 A5 JPWO2020030927 A5 JP WO2020030927A5 JP 2021506986 A JP2021506986 A JP 2021506986A JP 2021506986 A JP2021506986 A JP 2021506986A JP WO2020030927 A5 JPWO2020030927 A5 JP WO2020030927A5
Authority
JP
Japan
Prior art keywords
seq
peptide
cationic
hyp
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534131A (ja
JP7663492B2 (ja
JP2021534131A5 (https=
Publication date
Priority claimed from GBGB1812972.6A external-priority patent/GB201812972D0/en
Application filed filed Critical
Publication of JP2021534131A publication Critical patent/JP2021534131A/ja
Publication of JPWO2020030927A5 publication Critical patent/JPWO2020030927A5/ja
Publication of JP2021534131A5 publication Critical patent/JP2021534131A5/ja
Priority to JP2025062268A priority Critical patent/JP2025106403A/ja
Application granted granted Critical
Publication of JP7663492B2 publication Critical patent/JP7663492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506986A 2018-08-09 2019-08-09 細胞透過性ペプチド Active JP7663492B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062268A JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1812972.6 2018-08-09
GBGB1812972.6A GB201812972D0 (en) 2018-08-09 2018-08-09 Cell-penetrating peptides
PCT/GB2019/052247 WO2020030927A1 (en) 2018-08-09 2019-08-09 Cell-penetrating peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062268A Division JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Publications (4)

Publication Number Publication Date
JP2021534131A JP2021534131A (ja) 2021-12-09
JPWO2020030927A5 true JPWO2020030927A5 (https=) 2022-08-16
JP2021534131A5 JP2021534131A5 (https=) 2022-08-16
JP7663492B2 JP7663492B2 (ja) 2025-04-16

Family

ID=63667311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506986A Active JP7663492B2 (ja) 2018-08-09 2019-08-09 細胞透過性ペプチド
JP2025062268A Pending JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062268A Pending JP2025106403A (ja) 2018-08-09 2025-04-04 細胞透過性ペプチド

Country Status (12)

Country Link
US (2) US12268749B2 (https=)
EP (1) EP3833376A1 (https=)
JP (2) JP7663492B2 (https=)
KR (1) KR20210090157A (https=)
CN (1) CN113347989A (https=)
AU (2) AU2019317789B2 (https=)
BR (1) BR112021002447A2 (https=)
CA (1) CA3108876A1 (https=)
GB (1) GB201812972D0 (https=)
IL (2) IL318744A (https=)
MX (2) MX2021001545A (https=)
WO (1) WO2020030927A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200131231A1 (en) 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CN113453723A (zh) 2018-12-07 2021-09-28 牛津大学科技创新有限公司 接头
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2022192749A2 (en) * 2021-03-12 2022-09-15 Pepgen Inc. Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
PE20242357A1 (es) * 2021-06-23 2024-12-16 Entrada Therapeutics Inc Compuestos antisentido y metodos para dirigirse a repeticiones cug
WO2025264554A1 (en) * 2024-06-17 2025-12-26 Pepgen Inc. Antisense oligonucleotide conjugates targeting peripheral myelin protein 22 (pmp22) and methods of use thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
IL127773A0 (en) 1998-12-28 1999-10-28 Yeda Res & Dev Saccharide conjugates and pharmaceutical compositions comprising them
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
BRPI0415858A (pt) 2003-10-29 2007-01-09 Sonus Pharma Inc compostos de medicamentos terapêuticos modificados por tocoferol
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
IE20060565A1 (en) 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
US20080311040A1 (en) 2007-03-06 2008-12-18 Flagship Ventures METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
US20080306001A1 (en) 2007-04-04 2008-12-11 Anzelika Liik Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP3443976A1 (en) 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2009102075A1 (en) 2008-02-13 2009-08-20 Kao Corporation Method for producing hippocastanaceae plant seed extract
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
US8575305B2 (en) 2008-06-04 2013-11-05 Medical Research Council Cell penetrating peptides
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN112574988A (zh) 2008-10-24 2021-03-30 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
JP5786109B2 (ja) 2008-10-27 2015-09-30 プロセンサ テクノロジーズ ベー．フェー． Ｄｕｃｈｅｎｎｅ型筋ジストロフィーｍＲＮＡ前駆体のエクソン４５の効率的なスキッピングのための方法及び手段
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
LT2499249T (lt) 2009-11-12 2018-12-27 The University Of Western Australia Priešprasmės molekulės ir patologijų gydymo būdai
EP2579899B1 (en) 2010-06-14 2017-03-15 F. Hoffmann-La Roche AG Cell-penetrating peptides and uses thereof
EP2394665A1 (en) 2010-06-14 2011-12-14 F. Hoffmann-La Roche AG Cell-penetrating peptides and uses therof
WO2012012467A2 (en) 2010-07-19 2012-01-26 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
CN103998458B (zh) * 2011-08-30 2018-10-09 医学研究理事会 具有中央疏水域的细胞穿透肽
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
CN104428310A (zh) 2012-06-26 2015-03-18 弗·哈夫曼-拉罗切有限公司 细胞穿透肽和鉴定细胞穿透肽的方法
RU2670488C2 (ru) 2012-09-13 2018-10-23 Юниверсите Де Женев Новые проникающие в клетку пептиды
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
KR102240217B1 (ko) 2012-09-25 2021-04-14 젠자임 코포레이션 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
RS58529B1 (sr) 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
GB201314411D0 (en) * 2013-08-12 2013-09-25 Medical Res Council Peptide conjugates
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
WO2015113922A1 (en) 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
WO2015161255A1 (en) 2014-04-18 2015-10-22 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
GB201421379D0 (en) 2014-12-02 2015-01-14 Isis Innovation Ltd And Medical Res Council Molecule
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
KR20180002618A (ko) 2015-03-23 2018-01-08 립타이드 바이오사이언스, 인코포레이티드 항균 펩티드 및 이의 사용방법
JP6817288B2 (ja) 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
WO2017027848A1 (en) 2015-08-12 2017-02-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
US20200131231A1 (en) 2017-02-17 2020-04-30 Oxford University Innovation Limited Cell penetrating peptides
JP2020536058A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
WO2019067979A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
WO2019067975A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CN113453723A (zh) 2018-12-07 2021-09-28 牛津大学科技创新有限公司 接头
EP3955966A1 (en) 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
EP3987029A1 (en) 2019-06-19 2022-04-27 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
US20220288218A1 (en) 2019-07-09 2022-09-15 The Governors Of The University Of Alberta Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
GB201911403D0 (en) 2019-08-09 2019-09-25 Univ Oxford Innovation Ltd Conjugate and uses thereof
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
US20240189434A1 (en) 2021-03-12 2024-06-13 Pepgen Inc. Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates
WO2022192749A2 (en) 2021-03-12 2022-09-15 Pepgen Inc. Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates

Similar Documents

Publication Publication Date Title
JP2021534131A5 (https=)
RU2468080C2 (ru) Новый класс терапевтических белковых молекул
CN103998458B (zh) 具有中央疏水域的细胞穿透肽
Chen et al. Galactosylated histone-mediated gene transfer and expression
JP7269968B2 (ja) ペプチド担体上の多重オリゴヌクレオチド部分
JP7846169B2 (ja) 細胞透過性ペプチド
JP7678654B2 (ja) 複合体及びその使用
JP2010524849A5 (https=)
CA3040645A1 (en) Peptide-based non-proteinaceous cargo delivery
CN113347989A (zh) 细胞穿透肽
JPWO2020030927A5 (https=)
JP2020525462A (ja) 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物
AU2014267044A1 (en) Bacteriophage
WO1995006056A1 (en) Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CN116615227A (zh) 适用于Cas9-RNP和其他核蛋白负荷的转导的最小长度的穿梭剂肽及其变体
Olmez et al. Protein-peptide interactions revolutionize drug development
US20150329609A1 (en) Chimeric dystrophin proteins to treat dystrophinopathies
RU2771605C2 (ru) Пептиды для внутриклеточной доставки нуклеиновых кислот
JP2007536910A5 (https=)
JP2023545546A (ja) 遺伝子発現調節のための非アニオン性ポリヌクレオチド類似体のペプチドに基づく導入
RU2021105152A (ru) Проникающие в клетку пептиды
JP6994714B2 (ja) 抗ウイルス性ペプチドおよびその利用
US20230399378A1 (en) Peptide-based delivery of agents
CN100356981C (zh) 与人表皮生长因子受体egfr特异性结合的配体寡肽
JPWO2019002875A5 (https=)